![consumerism](jpg/healthcare_consumer-e1478497357270-150x150.jpg)
Allergies
-
FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine
ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.
-
Consumer / Employer, Health Tech
Allermi Raises $3.5M in Seed Funding To Grow DTC Allergy Relief Platform
Allermi’s $3.5 million seed funding was led by Nelstone Ventures and included participation from FourSight Capital Partners. The company will use the money to expand nationally.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Online allergy startup raises $1.25M in pre-seed round
Based in San Francisco, Allermi aims to create a national market for a customizable approach to allergy relief pioneered by a California doctor.
-
Imagine a world without disease
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
-
EverlyWell garners $2M to add more tests, staff for diagnostic testing startup
Julia Cheek, EverlyWell CEO and cofounder, said in an email that the funding will help the company expand its suite of tests, hire key leadership positions, launch new partnerships and enhance product features this year.
-
Allergy diagnostics market to reach $3.8bn by 2024
Rising rates of allergies worldwide will cause the global market for allergy diagnostics to nearly triple from $1.3 billion in 2015 to $3.8 billion in 2024, says a new report.
-
Top Story, Devices & Diagnostics
Innovation is in progress to replace the bulky EpiPen with something more practical
There must be some better, more efficient solutions for the essential use of the EpiPen, and Windgap Medical is working on it.
-
Morning Read: Abbott readies $25B bid for St Jude Medical, research suggests potential for allergy-free public parks
Drug developer Abbott Laboratories is poised to make a $25 billion bid for medical device maker St Jude Medical, allergy free parks could be a thing in the future.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Scientists developing potential cure for peanut allergies with surprising treatment: Peanuts
Nietzsche may have been thinking of emotional turmoil when he wrote “That which does not […]
-
Devices & Diagnostics, Diagnostics, Health IT
Smartphone as epidemiologist: App + cradle can detect food toxins and tainted water
A new smartphone biosensor may provide particularly helpful point-of-care possibilities for medicine in remote locations […]